- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.01. | Elutia reports 16% revenue growth, advances breast reconstruction product | 1 | Investing.com | ||
| 12.01. | Elutia sees Q4 net sales of $3.3M | 1 | Seeking Alpha | ||
| 12.01. | ELUTIA INC. - 8-K, Current Report | - | SEC Filings | ||
| 09.01. | Elutia Inc.: Elutia to Present at Global BioInnovation Forum on NXT-41x Biomatrix Program for Plastic and Reconstructive Surgery | 1 | GlobeNewswire (USA) | ||
| ELUTIA Aktie jetzt für 0€ handeln | |||||
| 02.01. | Elutia droht Delisting: NASDAQ-Anforderungen an Marktwert und Mindestkurs nicht erfüllt | 1 | Investing.com Deutsch | ||
| 02.01. | ELUTIA INC. - 8-K, Current Report | - | SEC Filings | ||
| 12.11.25 | ELUTIA INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11.25 | Elutia outlines plan for NXT-41x launch in $1.5B breast reconstruction market following $88M asset sale | 1 | Seeking Alpha | ||
| 06.11.25 | ELUTIA INC. - 8-K, Current Report | - | SEC Filings | ||
| 23.10.25 | Elutia Inc.: Elutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 | 2 | GlobeNewswire (USA) | ||
| 14.10.25 | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.10.25 | Elutia appoints medical tech veteran Guido Neels to board of directors | 1 | Investing.com | ||
| 10.10.25 | Elutia beruft Medizintechnik-Veteranen Guido Neels in den Verwaltungsrat | 1 | Investing.com Deutsch | ||
| 10.10.25 | Elutia Inc.: Elutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board of Directors | 2 | GlobeNewswire (USA) | ||
| 07.10.25 | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.10.25 | Elutia closes $88M bioenvelope sale to Boston Scientific | 7 | MassDevice | ||
| 01.10.25 | Elutia Inc.: Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million | 8 | GlobeNewswire (USA) | ||
| 16.09.25 | Elutia Inc.: Elutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of Reoperation | 1 | GlobeNewswire (USA) | ||
| 09.09.25 | Elutia To Sell EluPro And CanGaroo Bioenvelopes To Boston Scientific | 522 | AFX News | WASHINGTON (dpa-AFX) - Elutia Inc. (ELUT) has entered into a definitive agreement to sell its EluPro and CanGaroo bioenvelopes, designed to protect patients receiving implantable medical devices... ► Artikel lesen | |
| 09.09.25 | Elutia sells drug-eluting bioenvelope tech to Boston Scientific for $88M | 5 | MassDevice |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DISC MEDICINE | 56,12 | -21,67 % | Disc Medicine Inc: Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP | FDA acknowledged that AURORA and BEACON provided sufficient evidence that bitopertin significantly lowers PPIX and that there is a strong mechanistic and biological plausibility supporting the use... ► Artikel lesen | |
| ARCELLX | 68,50 | -0,22 % | Arcellx (ACLX) Shares Encouraging Data on Latest Laboratory Study | ||
| AVIDITY BIOSCIENCES | 72,88 | -0,05 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| QIAGEN | 42,905 | +0,13 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 46 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Inmitten der Übernahmespekulationen liefere der... ► Artikel lesen | |
| UPSTREAM BIO | 8,740 | -31,72 % | Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma | - Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing - - Verekitug also delivered... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 60,78 | -3,91 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| ZENAS BIOPHARMA | 26,520 | +1,57 % | Zenas BioPharma's MS drug shows 95% reduction in brain lesions | ||
| APOGEE THERAPEUTICS | 67,74 | -2,27 % | Here is Why Apogee Therapeutics (APGE) Appears Attractive | ||
| PRAXIS PRECISION MEDICINES | 317,31 | -4,69 % | Guggenheim Raises Price Target for Praxis Precision Medicines (PRAX) | ||
| RECURSION PHARMACEUTICALS | 3,495 | -2,37 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,930 | +3,71 % | Beam Therapeutics Inc. - 8-K, Current Report | ||
| ERASCA | 12,020 | -2,36 % | Stifel bestätigt Kaufempfehlung für Erasca mit Kursziel von 10 US-Dollar | ||
| MINERALYS THERAPEUTICS | 27,600 | -0,93 % | Mineralys Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| TANGO THERAPEUTICS | 12,900 | +1,82 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor | Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately... ► Artikel lesen | |
| IMMUNOME | 22,160 | -1,25 % | H.C. Wainwright initiates coverage on Immunome stock with Buy rating |
ELUTIA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +10,38 % bei einem Aktienkurs von 1,050 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELUTIA INC finden Sie auf Wallstreet Online.